Xspray Pharma’s HyNap-Dasa Shows Formal Bioequivalence
STOCKHOLM, SWEDEN – October 10, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) can today present data confirming formal bioequivalence for the company’s lead product candidate, HyNap-Dasa, compared to Sprycel® (dasatinib).”It has taken us three years of work to come to these encouraging results and the excitement in the company is clearly present today. We will now take serious steps in order to develop the business and as our technology is now proven we will seek partners for the commercial launch of HyNap-Dasa”, says Per Andersson, CEO of Xspray Pharma. Xspray Pharma today presents